Evidence map›Paper›PMID 26645892›Full record

ReviewThe Analyst2016

Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).

Michael Tu, David Chia, Fang Wei, David Wong

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Analyst, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Emerging technologies for salivaomics in cancer detection.Journal of cellular and molecular medicine · 2017
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael TuSchool of Dentistry, University of California, Los Angeles, CA, USA. emtu@ucla.edu frada@ucla.edu dtww@ucla.edu.
David ChiaDepartment of Pathology, UCLA David Geffen School of Medicine at UCLA, Los Angeles, California, USA. dchia@mednet.ucla.edu.
Fang WeiSchool of Dentistry, University of California, Los Angeles, CA, USA. emtu@ucla.edu frada@ucla.edu dtww@ucla.edu.
David WongSchool of Dentistry, University of California, Los Angeles, CA, USA. emtu@ucla.edu frada@ucla.edu dtww@ucla.edu.
University of California, Los Angeles · USLos Angeles City College · USUniversity of California System · US

Funding

UCLA Dentist-Scientist and Oral Health-Researcher Training ProgramT90DE022734 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2012 to 2017
$2.3M
NIDCR NIH HHS T90 DE022734NIDCR NIH HHS T90DE022734
6 · The paper itself

Abstract

Oncogenic activations by mutations in key cancer genes such as EGFR and KRAS are frequently associated with human cancers. Molecular targeting of specific oncogenic mutations in human cancer is a major therapeutic inroad for anti-cancer drug therapy. In addition, progressive developments of oncogene mutations lead to drug resistance. Therefore, the ability to detect and continuously monitor key actionable oncogenic mutations is important to guide the use of targeted molecular therapies to improve long-term clinical outcomes in cancer patients. Current oncogenic mutation detection is based on direct sampling of cancer tissue by surgical resection or biopsy. Oncogenic mutations were recently shown to be detectable in circulating bodily fluids of cancer patients. This field of investigation, termed liquid biopsy, permits a less invasive means of assessing the oncogenic mutation profile of a patient. This paper will review the analytical strategies used to assess oncogenic mutations from biofluid samples. Clinical applications will also be discussed.

Indexed as

ElectricityMutationBiopsyHumansNeoplasmsOncogenesPoint-of-Care SystemsPolymerase Chain Reaction

Identifiers

PMID26645892
PMCPMC4701580
OpenAlexW2191850806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.